Pharmaceutical Era

Search your requirement

  • Home
  • Press Releases
    • Submit Release
  • Events
  • Reach Us

Social media

Pharmaceutical Era Pharmaceutical Era
  • Home
  • Press Releases
    • Submit Release
  • Events
  • Reach Us
MilliporeSigma receives the industry
MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing
Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics
Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics
Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season
Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season
OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award
OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award
Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis
Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis
ProJenX announces the formation of its Clinical Advisory Board
ProJenX announces the formation of its Clinical Advisory Board
Citius Pharmaceuticals
Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma
NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients
NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients
Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits
Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.
Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic
Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic
FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma
FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

Featured Press Releases

Leading Dermatologist Dr. Dendy Engelman Joins ELASTEN® to Advance the Future of Science-Backed Skin Health from Within

Leading Dermatologist Dr. Dendy Engelman Joins ELASTEN® to Advance the Future of Science-Backed Skin Health from Within

  • By QUIRIS Healthcare
  • QUIRIS Healthcare
  • 11 Jun 2026
Breast Milk–Inspired Synbiotic for Infant Gut Health Developed Through Partnership Between NurtureBio and Lallemand

Breast Milk–Inspired Synbiotic for Infant Gut Health Developed Through Partnership Between NurtureBio and Lallemand

  • By NurtureBio
  • NurtureBio
  • 11 Jun 2026
SEREMI de Salud Grants Registration to Chile

SEREMI de Salud Grants Registration to Chile's First Finished Product Featuring Setria® Glutathione

  • By Kyowa Hakko U.S.A
  • Kyowa Hakko U.S.A
  • 11 Jun 2026
Roquette Highlights Scalable Innovations in Drug Delivery

Roquette Highlights Scalable Innovations in Drug Delivery

  • By Roquette
  • Roquette
  • 11 Jun 2026
X-Therma Launched XT-NoVo® and TimeSeal® Platform to Advance On-Demand Regenerative Medicine Beyond Cold Chain Constraints

X-Therma Launched XT-NoVo® and TimeSeal® Platform to Advance On-Demand Regenerative Medicine Beyond Cold Chain Constraints

  • By X-Therma Inc.
  • X-Therma Inc.
  • 11 Jun 2026
IMAAVY® (nipocalimab-aahu) demonstrated rapid onset and durable hemoglobin response in a pivotal Phase 2/3 study of warm autoimmune hemolytic anemia (wAIHA), a disease with no FDA-approved therapies

IMAAVY® (nipocalimab-aahu) demonstrated rapid onset and durable hemoglobin response in a pivotal Phase 2/3 study of warm autoimmune hemolytic anemia (wAIHA), a disease with no FDA-approved therapies

  • By Johnson & Johnson
  • Johnson & Johnson
  • 10 Jun 2026
Log in
Show
  • Create an account
  • Forgot your username?
  • Forgot your password?
The Digital Pharma Advances Conference 2026

Most Popular

  • Illumina
    Illumina's Constellation Mapped Read technology uncovers hard-to-see genomic insights in the GeneDx pilot
    By Illumina, Inc.
    Oct 15
  • PureWay and PPSWG Form New Partnership to Transform Pharmaceutical Waste Management in the U.S.
    PureWay and PPSWG Form New Partnership to Transform Pharmaceutical Waste Management in the U.S.
    By PureWay Compliance
    Jan 12
  • Lipella Pharmaceuticals initiates Phase 2a trial for LP-310 in oral lichen planus, enrolling the first patients
    Lipella Pharmaceuticals initiates Phase 2a trial for LP-310 in oral lichen planus, enrolling the first patients
    By Lipella Pharmaceuticals Inc
    Jul 29
July   2026
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

User Area

  • Login page
  • Registration
  • Edit Profile
  • Forgot Password

Discover

  • About Us
  • Terms Of Use
  • Privacy Policy
  • FAQs

Engage with Us

  • Search on Site
  • Post Press Release
  • Promote Brand
  • List Your Event

Subscribe to Our Monthly Newsletter

Subscribe to Pharmaceutical Era’s monthly newsletter, Pharmaceutical Leaders Digest®, to receive timely updates from across the pharmaceutical industry.
I agree with the Terms and conditions
×
and the Privacy policy
×
© Pharmaceutical Era — A product of HISSM. All Rights Reserved.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. To find out more, please click here.